INVICTUS MD STRATEGIES IVITF
INVICTUS MD STRATEGIES IVITF
Apertura: -
Cambio neto: -
Volumen: -
Mínimo: -
Máximo: -
Distancia Mín/Máx: -
Tipo: Acciones
Ticker: IVITF
ISIN: CA46183X2086

INVICTUS ANNOUNCES CHANGE TO BOARD

  • 65

Vancouver, B.C., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Vancouver, BC, December 13, 2019 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS2) announced today that Trevor Dixon has resigned from the Board of Directors of the Company effective immediately.  Marc Ripa has been appointed to the Board to fill the casual vacancy.

 

Mr. Ripa stated, “On behalf of the Board, we wish to thank Trevor for his service as both a Director and Officer of the Company and as President and Director of the Company’s wholly owned subsidiary Acreage Pharms Ltd. We wish him all the best.”

 

For more information, please visit www.invictus-md.com.

 

Marc Ripa

Chief Executive Officer

 

Investor Relations 1-844-800-6086

E-Mail: [email protected]

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

About Invictus

 

Invictus is a global cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the Company’s medical clients and retail customers. The Company’s integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and sales to provinces.

 

To meet growing demand, Invictus is expanding its cultivation footprint with two cannabis production facilities licensed under the Cannabis Act, which replaced the Access to Cannabis for Medical Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II facilities are in full production. Acreage is awaiting the amendment to their license from Health Canada to include the Phase III facility. AB Laboratories Inc., a company which is a 50% owned subsidiary of Invictus has completed its Phase II expansion and received its amended license from Health Canada. Another of Invictus’ wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise), continues to connect medical clients to physicians for medical cannabis and to Invictus’ fully licensed cannabis producers under the Cannabis Act. Invictus is targeting up to 50 percent of production to medical cannabis. Invictus drives sustainable long-term shareholder value by continuing to develop Invictus’ Canadian production of medical and recreational cannabis products. For more information visit www.invictus-md.com.

 

ti?nf=Nzc4MDU3MCMzMjY0NzcxIzIxMzY0NzU=
Kathy Love
Invictus 
[email protected]
GlobeNewsWire
GlobeNewsWire

GlobeNewswire es una de las redes de distribución de noticias por cable más grandes del mundo, que se especializa en la entrega de comunicados de prensa corporativos, divulgaciones financieras y contenido multimedia a los medios, inversionistas y lectores de todo el mundo.